NOTE 5 — NOTE RECEIVABLES

On May 10, 2025, the Company’s subsidiary FuAn entered into a short-term note receivable agreement with a third-party company Bio Essence Pharmaceutical Inc. (“BEP”) to lend $500,000 to Bio Essence at a fixed annual interest rate of 10% with maturity date on December 10, 2025. As of January 31, 2026, the Company had received $170,000 repayments from BEP. As of the reporting date, the Company and BEP is in the process of renewing the maturity date. 

On June 5, 2025 and July 10, 2025, the Company advanced $100,000 and $90,000, respectively, to BEP as a short-term borrowing with no interest. On August 4, 2025, the company received full repayment of $190,000 from BEP. 

On November 19, 2025, the Company entered into a short-term note receivable agreement with a third party company Valemi Inc. (“Borrower”), pursuant to which the Company loaned $500,000 to the Borrower. The note bears interest rate of 9% per annum, calculated on a simple interest basis, and is secured by corporate and personal guarantees. The outstanding principal balance and any accrued but unpaid interest are due and payable in full on May 18, 2026.

As of January 31,2026, the outstanding balance of note receivables was $830,000 and accrued interest receivable was $19,680. Interest income of $15,735 and $36,347 was recognized during the three and nine months ended January 31, 2026.